Skip to main content

Advertisement

SpringerLink
Log in

Management Strategies for Atypical Parkinsonism

  • Review
  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Abstract

Purpose of Review

Atypical parkinsonism is a term usually used to describe three neurodegenerative parkinsonian disorders: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA). In contrast to Parkinson’s disease, these disorders have a poor prognosis and present with a multitude of diverse symptoms, including parkinsonism, dystonia, myoclonus, gait disorders, dysarthria, dysphagia, sleep, cognitive, and behavioral disorders. In the absence of an approved disease-modifying treatment, symptomatic treatment is the mainstay of management. The purpose of this review is to present an overview of the management of these complex disorders, with a particular focus on a holistic and multidisciplinary approach.

Recent Findings

In addition to presenting the most significant pharmacological interventions for symptom management, data regarding non-pharmacological interventions are analyzed. Important non-pharmacological clinical practice questions such as breaking the news, palliative care, and end-of-life issues are discussed, in an effort to present an overview of the management of atypical parkinsonism from diagnosis to the most advanced stages of these diseases.

Summary

Management of atypical parkinsonian disorders includes symptomatic pharmacological and non-pharmacological interventions, in addition to addressing issues such as informing the patient of the diagnosis, palliative care, and end-of-life issues, which require a multidisciplinary approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

No datasets were generated or analyzed during the current study.

References

  1. Girgis A, Sanson-Fisher RW. Breaking bad news: consensus guidelines for medical practitioners. J Clin Oncol. 1995;13(9):2449–56.

    Article  CAS  PubMed  Google Scholar 

  2. McCluskey L, Casarett D, Siderowf A. Breaking the news: a survey of ALS patients and their caregivers. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(3):131–5.

    Article  PubMed  Google Scholar 

  3. Schmid Mast M, Kindlimann A, Langewitz W. Recipients’ perspective on breaking bad news: how you put it really makes a difference. Patient Educ Couns. 2005;58(3):244–51.

    Article  PubMed  Google Scholar 

  4. Wenning GK, Stankovic I, Vignatelli L, Fanciulli A, Calandra-Buonaura G, Seppi K, Palma JA, Meissner WG, Krismer F, Berg D, Cortelli P, Freeman R, Halliday G, Höglinger G, Lang A, Ling H, Litvan I, Low P, Miki Y, Panicker J, Pellecchia MT, Quinn N, Sakakibara R, Stamelou M, Tolosa E, Tsuji S, Warner T, Poewe W, Kaufmann H, et al. The movement disorder society criteria for the diagnosis of multiple system atrophy. Mov Disord. 2022;37(6):1131–48. https://doi.org/10.1002/mds.29005. PMID: 35445419 PMCID: PMC9321158.

  5. Borasio GD, Voltz R. Palliative care in amyotrophic lateral sclerosis. J Neurol. 1997;244(Suppl 4):S11–7.

    Article  PubMed  Google Scholar 

  6. Fanciulli A, Wenning GK. Multiple-system atrophy. N Engl J Med. 2015;372(14):1375–6.

    PubMed  Google Scholar 

  7. Wenning GK, et al. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12(2):133–47.

    Article  CAS  PubMed  Google Scholar 

  8. Kollensperger M, et al. Presentation, diagnosis, and management of multiple system atrophy in Europe: final analysis of the European multiple system atrophy registry. Mov Disord. 2010;25(15):2604–12.

    Article  PubMed  Google Scholar 

  9. Giagkou N, Stamelou M. Therapeutic management of the overlapping syndromes of atypical Parkinsonism. CNS Drugs. 2018;32(9):827–37.

    Article  PubMed  Google Scholar 

  10. Kompoliti K, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol. 1998;55(7):957–61.

    Article  CAS  PubMed  Google Scholar 

  11. Litvan I, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry. 1996;60(6):615–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Nath U, et al. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology. 2003;60(6):910–6.

    Article  CAS  PubMed  Google Scholar 

  13. Williams DR, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-Parkinsonism. Brain. 2005;128(Pt 6):1247–58.

    Article  PubMed  Google Scholar 

  14. Nieforth KA, Golbe LI. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol. 1993;16(4):338–46.

    Article  CAS  PubMed  Google Scholar 

  15. Birdi S, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord. 2002;17(6):1255–64.

    Article  PubMed  Google Scholar 

  16. Collins SJ, et al. Progressive supranuclear palsy: neuropathologically based diagnostic clinical criteria. J Neurol Neurosurg Psychiatry. 1995;58(2):167–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Arena JE, et al. Progressive supranuclear palsy: progression and survival. J Neurol. 2016;263(2):380–9.

    Article  PubMed  Google Scholar 

  18. Respondek G, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014;29(14):1758–66.

    Article  PubMed  Google Scholar 

  19. Frucht S, et al. Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration. Mov Disord. 2000;15(2):340–3.

    Article  CAS  PubMed  Google Scholar 

  20. Wenning GK, S. Working Group on Atypical Parkinsonism of the Austrian Parkinson’s. Placebo-controlled trial of amantadine in multiple-system atrophy. Clin Neuropharmacol. 2005;28(5):225–7.

    Article  CAS  PubMed  Google Scholar 

  21. Oertel W, et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord. 2017;32(12):1701–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Rascol O, et al. Fluoxetine for the symptomatic treatment of multiple system atrophy: the MSA-FLUO trial. Mov Disord. 2021;36(7):1704–11.

    Article  CAS  PubMed  Google Scholar 

  23. Seppi K, et al. Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurol. 2006;13(10):1146–8.

    Article  CAS  PubMed  Google Scholar 

  24. Rajrut AH, et al. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord. 1997;3(4):211–4.

    Article  CAS  PubMed  Google Scholar 

  25. Jackson JA, Jankovic J, Ford J. Progressive supranuclear palsy: clinical features and response to treatment in 16 patients. Ann Neurol. 1983;13(3):273–8.

    Article  CAS  PubMed  Google Scholar 

  26. Dale ML, et al. Associations between amantadine usage, gait, and cognition in PSP: a post-hoc analysis of the Davunetide trial. Front Neurol. 2020;11:606925.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. N Engl J Med. 1999;341(7):543–4.

    Article  CAS  PubMed  Google Scholar 

  28. Cotter C, Armytage T, Crimmins D. The use of zolpidem in the treatment of progressive supranuclear palsy. J Clin Neurosci. 2010;17(3):385–6.

    Article  CAS  PubMed  Google Scholar 

  29. Chang AY, Weirich E. Trial of zolpidem, eszopiclone, and other GABA agonists in a patient with progressive supranuclear palsy. Case Rep Med. 2014;2014:107064.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Mayr BJ, et al. Zolpidem in progressive supranuclear palsy. Eur J Neurol. 2002;9(2):184–5.

    Article  PubMed  Google Scholar 

  31. Apetauerova D, et al. CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. Neurol Neuroimmunol Neuroinflamm. 2016;3(5):e266.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Stamelou M, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23(7):942–9.

    Article  PubMed  Google Scholar 

  33. Fanciulli A, et al. Multiple system atrophy. Int Rev Neurobiol. 2019;149:137–92.

    Article  CAS  PubMed  Google Scholar 

  34. Ilg W, et al. Consensus paper: management of degenerative cerebellar disorders. Cerebellum. 2014;13(2):248–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Boesch SM, et al. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2002;72(3):300–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Müller J, et al. Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia. J Neurol. 2002;249(3):300–4.

    Article  PubMed  Google Scholar 

  37. Kanazawa M, et al. Botulinum toxin A injections improve apraxia of eyelid opening without overt blepharospasm associated with neurodegenerative diseases. Mov Disord. 2007;22(4):597–8.

    Article  PubMed  Google Scholar 

  38. Cho JW, Lee JH. Suppression of myoclonus in corticobasal degeneration by levetiracetam. J Mov Disord. 2014;7(1):28–30.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Kovacs T, et al. Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases. J Neural Transm (Vienna). 2009;116(12):1631–4.

    Article  PubMed  Google Scholar 

  40. Zampieri C, Di Fabio RP. Balance and eye movement training to improve gait in people with progressive supranuclear palsy: quasi-randomized clinical trial. Phys Ther. 2008;88(12):1460–73.

    Article  PubMed  Google Scholar 

  41. Gibbons CH, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017;264(8):1567–82.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Fanciulli A, et al. Elastic abdominal binders attenuate orthostatic hypotension in Parkinson’s disease. Mov Disord Clin Pract. 2016;3(2):156–60.

    Article  PubMed  Google Scholar 

  43. Veazie S, et al. Fludrocortisone for orthostatic hypotension. Cochrane Database Syst Rev. 2021;5(5):CD012868.

    PubMed  Google Scholar 

  44. Jankovic J, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95(1):38–48.

    Article  CAS  PubMed  Google Scholar 

  45. Low PA, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277(13):1046–51.

    Article  CAS  PubMed  Google Scholar 

  46. Kaufmann H, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Biaggioni I, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65(1):101–7.

    Article  CAS  PubMed  Google Scholar 

  48. Ramirez CE, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2014;64(6):1235–40.

    Article  CAS  PubMed  Google Scholar 

  49. Shibao C, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007;50(1):47–53.

    Article  CAS  PubMed  Google Scholar 

  50. Byun JI, et al. Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension. Ann Clin Transl Neurol. 2020;7(1):112–20.

    Article  CAS  PubMed  Google Scholar 

  51. Shibao C, et al. Comparative efficacy of yohimbine against pyridostigmine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2010;56(5):847–51.

    Article  CAS  PubMed  Google Scholar 

  52. Singer W, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol. 2006;63(4):513–8.

    Article  PubMed  Google Scholar 

  53. Byun JI, et al. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension. Neurology. 2017;89(10):1078–86.

    Article  CAS  PubMed  Google Scholar 

  54. Shibao C, et al. Acarbose, an alpha-glucosidase inhibitor, attenuates postprandial hypotension in autonomic failure. Hypertension. 2007;50(1):54–61.

    Article  CAS  PubMed  Google Scholar 

  55. Onrot J, et al. Hemodynamic and humoral effects of caffeine in autonomic failure. Therapeutic implications for postprandial hypotension. N Engl J Med. 1985;313(9):549–54.

    Article  CAS  PubMed  Google Scholar 

  56. Squair JW, et al. Implanted system for orthostatic hypotension in multiple-system atrophy. N Engl J Med. 2022;386(14):1339–44.

    Article  PubMed  Google Scholar 

  57. Jordan J, et al. Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. J Hypertens. 2019;37(8):1541–6.

    Article  CAS  PubMed  Google Scholar 

  58. Palma JA, Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 2018;33(3):372–90.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Chen TY, et al. Multi-centre study of intraurethral valve-pump catheter in women with a hypocontractile or acontractile bladder. Eur Urol. 2005;48(4):628–33.

    Article  PubMed  Google Scholar 

  60. Albanese A, et al. Multiple system atrophy presenting as Parkinsonism: clinical features and diagnostic criteria. J Neurol Neurosurg Psychiatry. 1995;59(2):144–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Giannantoni A, et al. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol. 2009;182(4):1453–7.

    Article  PubMed  Google Scholar 

  62. Hussain IF, et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001;71(3):371–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Raccagni C, et al. Female sexual dysfunction in multiple system atrophy: a prospective cohort study. Clin Auton Res. 2021;31(6):713–7.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Rohrer G, Hoglinger GU, Levin J. Symptomatic therapy of multiple system atrophy. Auton Neurosci. 2018;211:26–30.

    Article  PubMed  Google Scholar 

  65. Grossauer A, et al. Symptomatic care in multiple system atrophy: state of the art. Cerebellum. 2023;22(3):433–46.

    Article  PubMed  Google Scholar 

  66. Ralls F, Cutchen L. Respiratory and sleep-related complications of multiple system atrophy. Curr Opin Pulm Med. 2020;26(6):615–22.

    Article  CAS  PubMed  Google Scholar 

  67. Shimohata T, et al. Mechanisms and prevention of sudden death in multiple system atrophy. Parkinsonism Relat Disord. 2016;30:1–6.

    Article  PubMed  Google Scholar 

  68. Shimohata T, et al. Floppy epiglottis as a contraindication of CPAP in patients with multiple system atrophy. Neurology. 2011;76(21):1841–2.

    Article  CAS  PubMed  Google Scholar 

  69. Cortelli P, et al. Stridor in multiple system atrophy: consensus statement on diagnosis, prognosis, and treatment. Neurology. 2019;93(14):630–9.

    Article  PubMed  PubMed Central  Google Scholar 

  70. Frattali CM, et al. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: a pilot study. Dysphagia. 1999;14(3):165–8.

    Article  CAS  PubMed  Google Scholar 

  71. Nozaki S, et al. Effects of Lee Silverman Voice Treatment (LSVT LOUD) on swallowing in patients with progressive supranuclear palsy: a pilot study. Prog Rehabil Med. 2021;6:20210012.

    PubMed  PubMed Central  Google Scholar 

  72. Sale P, Castiglioni D, De Pandis MF, Torti M, Dall'armi V, Radicati FG, Stocchi F. The Lee Silverman Voice Treatment (LSVT®) speech therapy in progressive supranuclear palsy. Eur J Phys Rehabil Med. 2015;51(5):569–74.

  73. Hanson WR, Metter EJ. DAF as instrumental treatment for dysarthria in progressive supranuclear palsy: a case report. J Speech Hear Disord. 1980;45(2):268–76.

    Article  CAS  PubMed  Google Scholar 

  74. Dale ML, et al. Cerebellar rTMS for motor control in progressive supranuclear palsy. Brain Stimul. 2019;12(6):1588–91.

    Article  CAS  PubMed  Google Scholar 

  75. Litvan I, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57(3):467–73.

    Article  CAS  PubMed  Google Scholar 

  76. Fabbrini G, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand. 2001;103(2):123–5.

    Article  CAS  PubMed  Google Scholar 

  77. Liepelt I, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010;6(1):70–4.

    Article  CAS  PubMed  Google Scholar 

  78. Oyeka M, et al. Progressive supranuclear palsy: improvement in cognitive-behavioral disturbances and motor-function disabilities following treatment with antidepressants and cholinesterase inhibitors. Cureus. 2021;13(6):e15641.

    PubMed  PubMed Central  Google Scholar 

  79. Litvan I, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol. 1989;26(3):404–7.

    Article  CAS  PubMed  Google Scholar 

  80. Kishi T, Matsunaga S, Iwata N. Memantine for the treatment of frontotemporal dementia: a meta-analysis. Neuropsychiatr Dis Treat. 2015;11:2883–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Johnson NA, et al. Pilot trial of memantine in primary progressive aphasia. Alzheimer Dis Assoc Disord. 2010;24(3):308.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Shelley BP, et al. Is the pathology of corticobasal syndrome predictable in life? Mov Disord. 2009;24(11):1593–9.

    Article  PubMed  Google Scholar 

  83. Ling H, et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation Brain. 2010;133(Pt 7):2045–57.

    PubMed  Google Scholar 

  84. Lee SE, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):327–40.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Constantinides VC, et al. CSF biomarkers beta-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes. J Neurol Sci. 2017;382:91–5.

    Article  CAS  PubMed  Google Scholar 

  86. Constantinides VC, et al. Cerebrospinal fluid biomarker profiling in corticobasal degeneration: application of the AT(N) and other classification systems. Parkinsonism Relat Disord. 2021;82:44–9.

    Article  CAS  PubMed  Google Scholar 

  87. Kertesz A, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25(2):178–85.

    Article  CAS  PubMed  Google Scholar 

  88. Schneider LS, Gleason RP, Chui HC. Progressive supranuclear palsy with agitation: response to trazodone but not to thiothixine or carbamazepine. J Geriatr Psychiatry Neurol. 1989;2(2):109–12.

    Article  CAS  PubMed  Google Scholar 

  89. Quinones CP, Saranza G. Symptomatic relief of constant groaning in progressive supranuclear palsy with escitalopram. Parkinsonism Relat Disord. 2022;96:50–1.

    Article  PubMed  Google Scholar 

  90. Miyaoka T, et al. Fluvoxamine for the treatment of depression and parkinsonism in progressive supranuclear palsy. Int J Psychiatry Clin Pract. 2002;6(1):45–7.

    Article  CAS  PubMed  Google Scholar 

  91. Lebert F, et al. Frontotemporal dementia: a randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17(4):355–9.

    Article  CAS  PubMed  Google Scholar 

  92. Meyer S, et al. Citalopram improves obsessive-compulsive crossword puzzling in frontotemporal dementia. Case Rep Neurol. 2019;11(1):94–105.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Deakin JB, et al. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharmacology. 2004;172(4):400–8.

    Article  CAS  PubMed  Google Scholar 

  94. Moretti R, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49(1):13–9.

    Article  CAS  PubMed  Google Scholar 

  95. Rocca P, et al. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer’s disease: preliminary findings from a naturalistic, retrospective study. Psychiatry Clin Neurosci. 2007;61(6):622–9.

    Article  CAS  PubMed  Google Scholar 

  96. Leclair-Visonneau L, et al. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin Neurol Neurosurg. 2016;146:35–9.

    Article  PubMed  Google Scholar 

  97. Wen Y, Jiao B, Zhou Y. The application of deep brain stimulation for progressive supranuclear palsy: a systematic review. Front Neurol. 2022;13:827472.

    Article  PubMed  PubMed Central  Google Scholar 

  98. Meissner WG, et al. Outcome of deep brain stimulation in slowly progressive multiple system atrophy: a clinico-pathological series and review of the literature. Parkinsonism Relat Disord. 2016;24:69–75.

    Article  PubMed  Google Scholar 

  99. Di Luca DG, Ramirez-Gomez C, Germann J, Santyr B, Boutet A, Milosevic L, Lang AE, Kalia SK, Lozano AM, Fasano A. Deep brain stimulation of the globus pallidus internus and externus in multiple system atrophy. Mov Disord. 2023;38(11):2121–5. https://doi.org/10.1002/mds.29573. PMID: 37544011.

  100. Blaise AS, et al. Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy. Parkinsonism Relat Disord. 2022;100:41–4.

    Article  CAS  PubMed  Google Scholar 

  101. Bhidayasiri R, et al. Compassionate trial of levodopa carbidopa intestinal gel infusion in two patients with progressive supranuclear palsy. Clin Neurol Neurosurg. 2014;116:1–3.

    Article  PubMed  Google Scholar 

  102. Raccagni C, et al. Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: a prospective trial. Parkinsonism Relat Disord. 2019;67:60–5.

    Article  CAS  PubMed  Google Scholar 

  103. Sonoda Y, et al. Amelioration of motor and nonmotor symptoms in cortical cerebellar atrophy and multiple system atrophy-cerebellar type by inpatient rehabilitation: a retrospective study. Int J Rehabil Res. 2021;44(2):104–9.

    Article  PubMed  Google Scholar 

  104. Park A, et al. Swallowing outcomes following voice therapy in multiple system atrophy with dysphagia: comparison of treatment efficacy with Parkinson’s disease. Dysphagia. 2022;37(1):198–206.

    Article  PubMed  Google Scholar 

  105. Jain S, et al. Occupational therapy in multiple system atrophy: a pilot randomized controlled trial. Mov Disord. 2004;19(11):1360–4.

    Article  PubMed  Google Scholar 

  106. Steffen TM, et al. Long-term locomotor training for gait and balance in a patient with mixed progressive supranuclear palsy and corticobasal degeneration. Phys Ther. 2007;87(8):1078–87.

    Article  PubMed  Google Scholar 

  107. Suteerawattananon M, MacNeill B, Protas EJ. Supported treadmill training for gait and balance in a patient with progressive supranuclear palsy. Phys Ther. 2002;82(5):485–95.

    Article  PubMed  Google Scholar 

  108. Di Pancrazio L, et al. Combined rehabilitation program for postural instability in progressive supranuclear palsy. NeuroRehabilitation. 2013;32(4):855–60.

    Article  PubMed  Google Scholar 

  109. Wittwer JE, Winbolt M, Morris ME. A Home-Based, Music-Cued Movement Program Is Feasible and May Improve Gait in Progressive Supranuclear Palsy. Front Neurol. 2019;10:116.

    Article  PubMed  PubMed Central  Google Scholar 

  110. Clerici I, et al. Rehabilitation in progressive supranuclear palsy: effectiveness of two multidisciplinary treatments. PLoS ONE. 2017;12(2):e0170927.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Sale P, et al. Effects of robot assisted gait training in progressive supranuclear palsy (PSP): a preliminary report. Front Hum Neurosci. 2014;8:207.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Nicolai S, et al. Improvement of balance after audio-biofeedback. A 6-week intervention study in patients with progressive supranuclear palsy. Z Gerontol Geriatr. 2010;43(4):224–8.

    Article  CAS  PubMed  Google Scholar 

  113. Al-Mahrezi A, Al-Mandhar Z. Palliative Care: Time for Action. Oman Med J. 2016;31(3):161–3. https://doi.org/10.5001/omj.2016.32. PMCID: PMC4852088 PMID: 27162584.

  114. Wiblin L, Lee M, Burn D. Palliative care and its emerging role in Multiple System Atrophy and Progressive Supranuclear Palsy. Parkinsonism Relat Disord. 2017;34:7–14.

    Article  PubMed  Google Scholar 

  115. Malhi R, et al. Palliative care of the patient with dementia. Dela J Public Health. 2021;7(4):92–8.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Brown L, et al. Mortality and institutionalization after percutaneous endoscopic gastrostomy in Parkinson's disease and related conditions. Mov Disord Clin Pract. 2020;7(5):509–15.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Britton JE, et al. The use of percutaneous endoscopic gastrostomy (PEG) feeding tubes in patients with neurological disease. J Neurol. 1997;244(7):431–4.

    Article  CAS  PubMed  Google Scholar 

  118. American Geriatrics Society Ethics Committee and Clinical Practice and Models of Care Committee. American Geriatrics Society feeding tubes in advanced dementia position statement. J Am Geriatr Soc. 2014;62(8):1590–3.

    Article  Google Scholar 

  119. Ying I. Artificial nutrition and hydration in advanced dementia. Can Fam Physician. 2015;61(3):245–8, e125–8.e125–8.

Download references

Acknowledgement

The authors wish to thank Dr. Roberto Erro for reviewing their manuscript.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. First Department of Neurology, National and Kapodistrian University of Athens, Eginition Hospital, Athens, Greece

    Vasilios C. Constantinides MD, PhD, Nikolaos Giagkou MD, Maria-Evgenia Brinia MD, Christos Koros MD, PhD & Leonidas Stefanis MD, PhD

  2. Parkinson’s Disease and Movement Disorders Dept., HYGEIA Hospital, Erythroy Stavrou 9, 15123, Athens, Greece

    Maria Stamelou MD, PhD, FEAN

  3. Medical School, European University of Cyprus, Nicosia, Cyprus

    Maria Stamelou MD, PhD, FEAN

Authors
  1. Vasilios C. Constantinides MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikolaos Giagkou MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria-Evgenia Brinia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christos Koros MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leonidas Stefanis MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Stamelou MD, PhD, FEAN
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

V.C.C, M-E.B, and N.G wrote the main manuscript; V.C.C, M-E.B, and N.G prepared Tables 1 and 2; C.K., L.S., and M.S. reviewed the manuscript.

Corresponding author

Correspondence to Maria Stamelou MD, PhD, FEAN.

Ethics declarations

Conflict of Interest

Vasilios C. Constantinides declares that he has no conflict of interest.

Nikolaos Giagkou declares that he has no conflict of interest.

Maria-Evgenia Brinia declares that she has no conflict of interest.

Christos Koros declares that he has no conflict of interest.

Leonidas Stefanis declares that he has no conflict of interest.

Maria Stamelou declares that she has no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Strategies of atypical parkinsonism.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Constantinides, V.C., Giagkou, N., Brinia, ME. et al. Management Strategies for Atypical Parkinsonism. Curr Treat Options Neurol 26, 169–187 (2024). https://doi.org/10.1007/s11940-024-00787-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-024-00787-6

Keywords

Search

Navigation